High Performance liquid chromatographic Method for the Determination of Sofosbuvir in pharmaceutical dosage forms

Sofosbuvir (brandnames Sovaldi, Hepcinat, Resof, Hep cvir, and SoviHep) is a nucleotide analog used in combination with other drugs for the treatment of hepatitis C virus (HCV) infection. Sovaldi® 40 mg Film-coated tablet are manufactured by Gilead Sciences. They are used for oral administration and available in 40 mg, 30 mg, or 20 mg of Sofosbuvir (equivalent to 59.12 mg, 44.34 mg, or 29.56 mg Sofosbuvirdimaleate, respectively) [2]. There are no analytical methods that have been reported for the estimation of Sofosbuvir in bulk and in pharmaceutical formulations [3-15]. The present HPLC method deals with new simple, accurate and reliable estimation of Sofosbuvir in sterile pharmaceutical tablets. The other methods reported mainly on the determination of Sofosbuvir in plasma, blood samples and biological fluids including tissue homogenates. Such methods may not be suitable for regular/routine analysis for Sofosbuvir in pharmaceutical industry because of diversity and complexity in sample matrix.

[1]  Iris R. Mabry-Hernandez,et al.  Screening for hepatitis C virus infection. , 2012, Gastroenterology & hepatology.

[2]  S. Zeuzem,et al.  Perspectives and challenges of interferon-free therapy for chronic hepatitis C. , 2013, Journal of hepatology.

[3]  W. Symonds,et al.  Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects , 2012, Antimicrobial Agents and Chemotherapy.

[4]  M. Otto,et al.  Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus , 2012, Antimicrobial Agents and Chemotherapy.

[5]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[6]  F. S. Domingues,et al.  Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients , 2009, Hepatology.

[7]  E. Schiff,et al.  Hepatitis C virus infection in USA: an estimate of true prevalence , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[8]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[9]  P. Marcellin,et al.  Treatment of chronic viral hepatitis. , 1994, Bailliere's clinical gastroenterology.

[10]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[11]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[12]  R. Bartenschlager,et al.  Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity , 1997, Journal of virology.

[13]  M. Otto,et al.  Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 , 2010, The Journal of Biological Chemistry.

[14]  M. Otto,et al.  Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. , 2010, Journal of medicinal chemistry.

[15]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[16]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.